Understanding GLP-1 Medication Coverage and Appeals Process

Learn about GLP-1 medication coverage, reasons for denials, and how to appeal effectively.

GLP-1 Medication Coverage

GLP-1 medications, such as Wegovy and Ozempic, may be covered under certain conditions. Wegovy has an FDA indication to reduce cardiovascular risk in adults with established cardiovascular disease and obesity or overweight, which can be a covered medical indication.

For medications like semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound), coverage is more readily available for patients diagnosed with Type 2 diabetes. If a diabetes diagnosis applies, it is beneficial to frame the request around this condition. Additionally, documented comorbidities such as sleep apnea, hypertension, or dyslipidemia can help a patient with a BMI of 27 qualify for coverage.

Reasons for Denial

There are several common reasons for denial of GLP-1 medication coverage. These include plans that exclude weight-loss drugs entirely, which is often a benefit-design denial rather than a clinical one. Other reasons may include insufficient documentation of BMI or comorbidities at the time of the request, failure to complete step therapy, or requests for off-label use of the medication.

Missing documentation for required diet or lifestyle programs, or the drug not being on the plan's formulary can also lead to denials.

Appealing a Denial

If a GLP-1 medication is denied, there is an appeal process that can be followed. The first step is to submit an internal appeal with a letter of medical necessity that ties the documented record to each criterion required by the insurance plan. A peer-to-peer review can also be requested, where the prescriber speaks directly with the plan's medical director.

If the initial appeal is unsuccessful, additional documentation can be submitted in a second internal appeal. If the denial persists, an external review by an independent organization may be pursued. It's important to note that if the denial is due to a hard benefit exclusion, appeals may not change the outcome, and alternative paths such as cash-pay options or pivoting to a covered indication may be necessary.